Current and historical daily PE Ratio for Roquefort Therapeutics PLC (
) from 2021 to Jun 10 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Roquefort Therapeutics PLC stock (LSE:ROQ) PE ratio as of Jun 10 2024 is 0.
More Details
Roquefort Therapeutics PLC (LSE:ROQ) PE Ratio (TTM) Chart
Roquefort Therapeutics PLC (LSE:ROQ) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 367
- 1
- 2
- 3
- 4
- 5
Roquefort Therapeutics PLC PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-10 | At Loss | 2024-04-04 | At Loss |
2024-06-07 | At Loss | 2024-04-03 | At Loss |
2024-06-06 | At Loss | 2024-04-02 | At Loss |
2024-06-05 | At Loss | 2024-03-28 | At Loss |
2024-06-04 | At Loss | 2024-03-27 | At Loss |
2024-06-03 | At Loss | 2024-03-26 | At Loss |
2024-05-31 | At Loss | 2024-03-25 | At Loss |
2024-05-30 | At Loss | 2024-03-22 | At Loss |
2024-05-29 | At Loss | 2024-03-21 | At Loss |
2024-05-28 | At Loss | 2024-03-20 | At Loss |
2024-05-24 | At Loss | 2024-03-19 | At Loss |
2024-05-23 | At Loss | 2024-03-18 | At Loss |
2024-05-22 | At Loss | 2024-03-15 | At Loss |
2024-05-21 | At Loss | 2024-03-14 | At Loss |
2024-05-20 | At Loss | 2024-03-13 | At Loss |
2024-05-17 | At Loss | 2024-03-12 | At Loss |
2024-05-16 | At Loss | 2024-03-11 | At Loss |
2024-05-15 | At Loss | 2024-03-08 | At Loss |
2024-05-14 | At Loss | 2024-03-07 | At Loss |
2024-05-13 | At Loss | 2024-03-06 | At Loss |
2024-05-10 | At Loss | 2024-03-05 | At Loss |
2024-05-09 | At Loss | 2024-03-04 | At Loss |
2024-05-08 | At Loss | 2024-03-01 | At Loss |
2024-05-07 | At Loss | 2024-02-29 | At Loss |
2024-05-03 | At Loss | 2024-02-28 | At Loss |
2024-05-02 | At Loss | 2024-02-27 | At Loss |
2024-05-01 | At Loss | 2024-02-26 | At Loss |
2024-04-30 | At Loss | 2024-02-23 | At Loss |
2024-04-29 | At Loss | 2024-02-22 | At Loss |
2024-04-26 | At Loss | 2024-02-21 | At Loss |
2024-04-25 | At Loss | 2024-02-20 | At Loss |
2024-04-24 | At Loss | 2024-02-19 | At Loss |
2024-04-23 | At Loss | 2024-02-16 | At Loss |
2024-04-22 | At Loss | 2024-02-15 | At Loss |
2024-04-19 | At Loss | 2024-02-14 | At Loss |
2024-04-18 | At Loss | 2024-02-13 | At Loss |
2024-04-17 | At Loss | 2024-02-12 | At Loss |
2024-04-16 | At Loss | 2024-02-09 | At Loss |
2024-04-15 | At Loss | 2024-02-08 | At Loss |
2024-04-12 | At Loss | 2024-02-07 | At Loss |
2024-04-11 | At Loss | 2024-02-06 | At Loss |
2024-04-10 | At Loss | 2024-02-05 | At Loss |
2024-04-09 | At Loss | 2024-02-02 | At Loss |
2024-04-08 | At Loss | 2024-02-01 | At Loss |
2024-04-05 | At Loss | 2024-01-31 | At Loss |
Roquefort Therapeutics PLC (LSE:ROQ) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
Roquefort Therapeutics PLC
ISIN : GB00BMDQ2T15
Description
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.